close
 |
Clear My Agenda & Abstract Book |
Print My Agenda |
Print My Abstract Book
Download My Agenda in PDF | Download My Agenda in iCal
Download My Agenda in PDF | Download My Agenda in iCal
HPV 2010 Programme
>> Day 3 - Monday, July 5, 2010
| Time | Description | Room |
Expand all sessions
|
|||
|---|---|---|---|---|---|---|
| 07:00 AM |
Early-Morning Workshop - Emerging Nations Capacity Building – PATH - Cervical Cancer screening |
515ab |
Add to my agenda | |||
| 07:00 AM |
Early-Morning Workshop - Young Researchers Community of Practice |
516bcd |
Show details | |||
|
07:00 AM |
L |
How to Improve Oral Scientific Communications
|
516bcd |
Add to my agenda | ||
|
07:00 AM |
L |
How to Improve Oral Scientific Communications
|
516bcd |
Add to my agenda | ||
| 08:00 AM |
Plenary - HPV Vaccination Chair(s): Tom Broker, Birmingham, USA François Coutlée, Montreal, Canada |
517cd |
Show details | |||
|
08:15 AM |
L |
Nomenklatura
|
517cd |
Add to my agenda | ||
|
08:30 AM |
L |
Population-level effectiveness of HPV vaccination: impact of herd immunity
|
517cd |
Add to my agenda | ||
|
09:00 AM |
L |
Therapeutic Vaccines for Chronic Infection and Cancer: Barriers and Hopes
|
517cd |
Add to my agenda | ||
|
09:30 AM |
L |
Evaluation of HPV Vaccination Programs
|
517cd |
Add to my agenda | ||
| 10:30 AM |
Satellite Symposium - Enhancing HPV prevention among indigenous populations: International perspectives on health and well being More Details... Chair(s): George Wurtak, Winnipeg, Canada Katherine Dinner, Ottawa, Canada |
516bcd |
Show details | |||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
| 10:30 AM |
Oral Communications - Clinical Science 1 Chair(s): Craig Meyers, Hershey, USA Charles JN Lacey, York, United Kingdom |
517a |
Show details | |||
|
10:30 AM |
L |
HPV-associated Cancers in HIV-infected and HIV-uninfected Individuals
|
517a |
Add to my agenda | ||
|
10:45 AM |
L |
Increased incidence of anal cancer and the precursor lesions in Danish women and men from 1978 - 2008
|
517a |
Add to my agenda | ||
|
11:00 AM |
L |
Anal cancer in HIV-positive men who have sex with men: results of a prospective study from Germany
|
517a |
Add to my agenda | ||
|
11:15 AM |
L |
The risk of anal and cervical HPV acquisition after multiple HPV-type infection at the other anatomic site
|
517a |
Add to my agenda | ||
|
11:30 AM |
L |
Development of genital warts after incident detection of HPV infection in young men
|
517a |
Add to my agenda | ||
|
11:45 AM |
L |
Highly active antiretroviral therapy (HAART) protects against Anal Intraepithelial Neoplasia 2/3 in HIV-seropositive men in Montreal
|
517a |
Add to my agenda | ||
| 10:30 AM |
Satellite Symposium - WHO HPV LabNet symposium: Laboratory testing in HPV vaccinology and HPV surveillance Chair(s): Joakim Dillner, Malmö, Sweden Elizabeth Unger, Atlanta, United States |
515ab |
Show details | |||
|
|
L |
Introduction and LabNet overview
|
515ab |
Add to my agenda | ||
|
|
L |
HPV LabNet GRL USA and HPV surveillance in the USA
|
515ab |
Add to my agenda | ||
|
|
L |
WHO HPV LabNet Proficiency Studies on HPV DNA genotyping and HPV serology
|
515ab |
Add to my agenda | ||
|
|
L |
National Reference Laboratory (NRL) for France: A national program for HPV Genotyping in France
|
515ab |
Add to my agenda | ||
|
|
L |
RRL (Regional Reference Laboratory) EMRO, Tunisia: Implementing HPV surveillance and HPV vaccine in low resource countries: Challenges, potential solutions and perspectives
|
515ab |
Add to my agenda | ||
|
|
L |
Development and Operation of an HPV quality assurance programme in Scotland
|
515ab |
Add to my agenda | ||
|
|
L |
HPV quality assurance and surveillance in South Africa
|
515ab |
Add to my agenda | ||
|
|
L |
Aims and duties of the German National Reference Center for Papilloma- and Polyomaviruses
|
515ab |
Add to my agenda | ||
|
|
L |
RRL Argentina: Activities of the Regional Reference Laboratory for the Americas
|
515ab |
Add to my agenda | ||
|
|
L |
NRL England: HPV vaccine surveillance and associated R&D
|
515ab |
Add to my agenda | ||
|
03:23 PM |
L |
NRL Norway: HPV vaccine surveillance in pre-screening age cohorts in Norway: HPV testing in urine samples
|
515ab |
Add to my agenda | ||
| 10:30 AM |
Oral Communications - Basic Science 1 Chair(s): Elliot J. Androphy, Worcester, USA Lawrence Banks, Trieste, Italy |
517b |
Show details | |||
|
10:30 AM |
L |
Role of E6 in the HPV16 life cycle
|
517b |
Add to my agenda | ||
|
10:45 AM |
L |
Cytoplasmic poly(A) binding proteins increase telomerase in HPV 16E6 expressing keratinocytes
|
517b |
Add to my agenda | ||
|
11:00 AM |
L |
hpv oncogenes modulate cell adhesion genes through a p63 pathway in caski cells
|
517b |
Add to my agenda | ||
|
11:15 AM |
L |
Telomere elongation-independent cell immortalization by HPV oncoproteins
|
517b |
Add to my agenda | ||
|
11:30 AM |
L |
p63 supports proliferation of normal keratinocytes and cervical cancer cells via Notch1 repression
|
517b |
Add to my agenda | ||
|
11:45 AM |
L |
Divergent transcriptional alterations in response to HPV16 & HPV18 E7 in primary human keratinocytes
|
517b |
Add to my agenda | ||
| 10:30 AM |
Oral Communications - Epidemiology & Public Health 1 Chair(s): Cosette Wheeler, Albuquerque, USA Jose A. Jeronimo, Seattle, USA |
524 |
Show details | |||
|
10:30 AM |
L |
Why an HPV vaccine register? Coverage estimates from and role of the National HPV Vaccination Program Register, Australia
|
524 |
Add to my agenda | ||
|
10:45 AM |
L |
Incidence rates of detection of HPV 6, 11, 16, or 18 in a cohort of more than 2,000 young men in 14 countries
|
524 |
Add to my agenda | ||
|
11:00 AM |
L |
Incidence,persistence,and determinants of HPV infection in a population of Inuit women in Nunavik, Quebec
|
524 |
Add to my agenda | ||
|
11:15 AM |
L |
TP53 codon 72 polymorphism and cervical cancer: a meta-analysis of published data
|
524 |
Add to my agenda | ||
|
11:30 AM |
L |
Will young women have a free HPV vaccine and will it impact on cervical screening? An analysis from Victoria, Australia
|
524 |
Add to my agenda | ||
|
11:45 AM |
L |
HPV infection in young male and female STI-clinic attendees in The Netherlands
|
524 |
Add to my agenda | ||
| 12:30 PM |
Satellite Lunch Symposium - Sponsored by Roche Molecular Systems, Inc. – DISPELLING THE MYTH THAT ALL HIGH RISK HPV GENOTYPES ARE THE SAME |
710 |
Show details | |||
|
|
L |
A new era begins (introduction)
|
710 |
Add to my agenda | ||
|
|
L |
Beyond the myth: HPV 16/18 in practice
|
710 |
Add to my agenda | ||
|
|
L |
The quest for new knowledge: Improving ASC-US management
|
710 |
Add to my agenda | ||
|
|
L |
Dawn of a new era: Targeted screening for patients with hidden disease
|
710 |
Add to my agenda | ||
|
|
L |
ATHENA: wisdom, endeavor, reason (closing)
|
710 |
Add to my agenda | ||
| 02:00 PM |
Satellite Symposium - Gender, HPV infection & HPV vaccination: the invisible man More Details... Chair(s): Zeev Rosberger, Montreal, Canada Gregory D. Zimet, Indianapolis, USA |
516bcd |
Show details | |||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
How Does Sexual Orientation Affect Men's Understanding of HPV and HPV Vaccine
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
|
|
L |
-
|
516bcd |
Add to my agenda | ||
| 02:00 PM |
Oral Communications - Basic Science 2 Chair(s): Laimonis A. Laimins, Chicago, USA Robert David Burk, Bronx, USA |
517b |
Show details | |||
|
02:00 PM |
L |
Immunogenic Display of Cross-Neutralizing L2 Peptides on bacteriophage Virus-like Particles
|
517b |
Add to my agenda | ||
|
02:15 PM |
L |
HPV6, 11, 16, and 18 Immunogenicity of four multi-valent HPV vaccine formulations in non-human primates
|
517b |
Add to my agenda | ||
|
02:30 PM |
L |
Multimeric L2 Vaccine Approach for Prevention of Bovine and Canine Papillomavirus Infections
|
517b |
Add to my agenda | ||
|
02:45 PM |
L |
Chimeric HPV16L1-16L2 virus-like particles (RG1-VLP) cause enduring cross-neutralization antibodies against mucosal and cutaneous HPV
|
517b |
Add to my agenda | ||
|
03:00 PM |
L |
HPV16/18 L1 VLP Vaccine Induces Cross-Neutralizing Antibodies that May Mediate Cross-Protection
|
517b |
Add to my agenda | ||
|
03:15 PM |
L |
L2 vaccine-induced antibodies have greater potency in vivo than predicted from in vitro assays
|
517b |
Add to my agenda | ||
| 02:00 PM |
Oral Communications - Clinical Science 2 Chair(s): K. Joan Murphy, Toronto Zeyi Cao, Beijing, China |
517a |
Show details | |||
|
02:00 PM |
L |
Triage of ASC-US and LSIL by p16/Ki-67 Dual-stained cytology: Results from the EEMAPS study
|
517a |
Add to my agenda | ||
|
02:15 PM |
L |
Triage of Pap negative, HPV positive screening test results using p16/Ki-67 Dual-stained Cytology
|
517a |
Add to my agenda | ||
|
02:30 PM |
L |
Clinical performance of a broad-spectrum RNA assay in a high-prevalence disease setting.
|
517a |
Add to my agenda | ||
|
02:45 PM |
L |
Pooling longitudinal results of randomised trials comparing cytological and HPV-based screening for cervical cancer
|
517a |
Add to my agenda | ||
|
03:00 PM |
L |
Impact of performing multiple biopsies on the detection of precancer in the NCI-OUHSC Biopsy Study
|
517a |
Add to my agenda | ||
|
03:15 PM |
L |
Cervical cancer epidemiology among HIV-infected women in North America
|
517a |
Add to my agenda | ||
| 02:00 PM |
Oral Communications - Epidemiology & Public Health 2 Chair(s): Luisa Villa, Sao Paulo, Brazil Jennifer S. Smith, Raleigh , USA |
524 |
Show details | |||
|
02:00 PM |
L |
Prevalence incidence and persistence of genital HPV infection in women between the ages of 25 and 45
|
524 |
Add to my agenda | ||
|
02:15 PM |
L |
The psychological impact of anal cancer screening on HIV+ men
|
524 |
Add to my agenda | ||
|
02:30 PM |
L |
Risk of Cervical and Vulvar Cancers Associated with Variation in Immune Response and HPV Related Genes
|
524 |
Add to my agenda | ||
|
02:45 PM |
L |
HPV prevalence, incidence and persistence among high risk HIV-negative and HIV-positive women in Kigali, Rwanda.
|
524 |
Add to my agenda | ||
|
03:00 PM |
L |
A national outcome for quadrivalent HPV vaccination: declining rates of genital warts in Australia
|
524 |
Add to my agenda | ||
|
03:15 PM |
L |
Increasing burden of HPV-associated anal cancer in Australia
|
524 |
Add to my agenda | ||
| 04:00 PM |
Oral Communications - Clinical Science 3 Chair(s): Allan Hildesheim, Rockville, USA Lorraine Elit, Hamilton, Canada |
517a |
Show details | |||
|
04:00 PM |
L |
Genotype-specific natural history of oral HPV infections among young mothers followed-up for 6-years in the prospective Finnish Family HPV Study
|
517a |
Add to my agenda | ||
|
04:15 PM |
L |
On Epithelial-Mesenchymal Transition in HPV-associated HNSCC: Immunohistochemical Analysis
|
517a |
Add to my agenda | ||
|
04:30 PM |
L |
Viral Oncogene expression Defines Oropharynx Carcinomas with Active HPV16 Involvement
|
517a |
Add to my agenda | ||
|
04:45 PM |
L |
HPV in oral mucosa of newborn and their concordance with HPV types in mother's cervical sample taken before delivery
|
517a |
Add to my agenda | ||
|
05:00 PM |
L |
Expression of EBV Latency Genes is associated with the Development of HPV-related Cervical Dysplasia in HIV+ Women
|
517a |
Add to my agenda | ||
|
05:15 PM |
L |
Oral HPV persistence at 6- and 12- months among healthy men: The HIM Study
|
517a |
Add to my agenda | ||
| 04:00 PM |
Oral Communications - Basic Science 3 Chair(s): Peter Snijders, Amsterdam, Netherlands Zhi-Ming Zheng, Bethesda, USA |
517b |
Show details | |||
|
04:00 PM |
L |
Hpv16 e2 is an immediate early marker of viral infection, preceding e7 expression in cin
|
517b |
Add to my agenda | ||
|
04:15 PM |
L |
The hpv-18 e2 protein interactome suggests implication of e2 in novel cellular pathways
|
517b |
Add to my agenda | ||
|
04:30 PM |
L |
Lack of DNA damage checkpoint regulation for HPV DNA replication: a reason for integration?
|
517b |
Add to my agenda | ||
|
04:45 PM |
L |
Papillomavirus infection requires γ secretase
|
517b |
Add to my agenda | ||
|
05:00 PM |
L |
HPV16 E2 inhibits polyadenylation and induces HPV late gene expression
|
517b |
Add to my agenda | ||
|
05:15 PM |
L |
Brd4 contacts selective HPV E2 and transcriptional regulators in a phosphorylation-dependent manner
|
517b |
Add to my agenda | ||
| 04:00 PM |
Satellite Symposium - CIN2 workshop More Details... Chair(s): Laura Koutsky, Seattle, USA Phillip Castle, Bethesda, USA |
515ab |
Show details | |||
|
04:00 PM |
L |
Introduction
|
515ab |
Add to my agenda | ||
|
04:10 PM |
L |
CIN2 from a Pathologist's perspective
|
515ab |
Add to my agenda | ||
|
04:20 PM |
L |
CIN2 diagnosed in young women
|
515ab |
Add to my agenda | ||
|
04:30 PM |
L |
CIN2 diagnosed in older women
|
515ab |
Add to my agenda | ||
|
04:40 PM |
L |
Biomarkers for triaging CIN2
|
515ab |
Add to my agenda | ||
|
04:50 PM |
L |
Summary
|
515ab |
Add to my agenda | ||
| 04:00 PM |
Oral Communications - Epidemiology & Public Health 3 Chair(s): William Bonnez, Rochester, USA |
524 |
Show details | |||
|
04:00 PM |
L |
HPV VACCINE INTRODUCTION IN EUROPE: LESSONS LEARNED
|
524 |
Add to my agenda | ||
|
04:15 PM |
L |
Plasma Micronutrients and the Acquisition and Clearance of Anal HPV Infection: Hawaii HPV Cohort Study
|
524 |
Add to my agenda | ||
|
04:30 PM |
L |
High-grade anal intra-epithelial neoplasia in homosexual men: data from two community-based cohorts
|
524 |
Add to my agenda | ||
|
04:45 PM |
L |
Acceptability of the HPV vaccine for males: A review of the literature
|
524 |
Add to my agenda | ||
|
05:00 PM |
L |
Continued rapid decline in warts after national quadrivalent HPV vaccine program
|
524 |
Add to my agenda | ||
|
05:15 PM |
L |
The Prevalence of Type-Specific Human Papillomavirus Infection in the Northwest Territories
|
524 |
Add to my agenda | ||
| 04:00 PM |
Satellite Symposium - Global HPV Vaccine - Implementation and Monitoring Roundtable More Details... Chair(s): Mona Saraiya, Atlanta, USA Lauri Markowitz, Atlanta, USA |
516abc |
Add to my agenda | |||
| 05:30 PM |
Evening Symposium - Sponsored By Qiagen – THE LEADER IN HPV TESTING NOW AND IN THE FUTURE Chair(s): Attila Larinez, London, United Kingdom |
710 |
Show details | |||
|
|
L |
HPV testing in primary screening
|
710 |
Add to my agenda | ||
|
|
L |
QIAGEN’s QIAensemble and careHPV platforms
|
710 |
Add to my agenda | ||
| 07:00 PM |
Evening event - Young Researchers Reception |
Add to my agenda | ||||
